Postzygotic mutations are acquired in all of the normal tissues throughout an individual's lifetime and hold 34 clues for identifying mutagenesis causing factors. The process and underlying mechanism of postzygotic 35 mutations in normal tissues is still poorly understood. In this study, we investigated postzygotic mutation 36 spectra in healthy individuals by optimized ultra-deep exome sequencing of time series samples from the 37 same volunteer and samples from different individuals. In cells of blood, sperm, and muscle, we resolved 38 three common types of mutational signature. Two of them are known to represent clock-like mutational 39 processes, and their proportions in mutation profiles associated with polymorphisms of epigenetic regulation 40 genes, suggesting the contribution of personal genetic backgrounds to underlying biological process. Notably, 41 the third signature, characterized by C>T transitions at GpCpN sites, tends to be a feature of diverse normal 42 tissues. Mutations of this type were likely to occur early in embryo development even before the tissue 43 differentiation, as indicated by their relatively high allele frequencies, sharing variants between multiple 44 tissues, and lacking of age-related accumulation. Almost all tumors shown in public datasets did not have 45 this signature detected except for 19.6% of clear cell renal cell carcinoma samples, which featured by 46 activation of the hypoxia-induced signaling pathway. Moreover, in vitro activation of HIF signaling pathway 47 successfully introduced the corresponding mutation profile of this signature in a culture-expanded human 48 embryonic stem cell line. Therefore, embryonic hypoxia may explain this novel signature across multiple 49 normal tissues. Our study suggest hypoxic conditions in the early stage of embryo development may be a 50 crucial factor for the C>T transitions at GpCpN sites and individual genetic background also related to 51 shaping human postzygotic mutation profiles. 52 53 Author Summary 54 The process and related mechanism of post-zygotic mutations in normal tissues is still poorly understood. 55
Introduction

65
After fertilization, most genomic mutations typically occur as a result of replication errors, DNA structure 66 instability, as well as other endogenous and exogenous sources, resulting in the genotypic and phenotypic 67 heterogeneity of all types of cells in the body [1] [2] [3] . In particular, mutations can be triggered by distinct 68 environmental factors, producing characteristic patterns. The accumulation of somatic mutations is believed 69 to chronicle the exposures, toxicity, regeneration and clonal structure of the progresses from health to disease 70 [4] [5] [6] . Thus, the roles of somatic mutations in pathogenesis have been widely explored [7, 8] . Moreover, in 71 recent years, multiple cell clones with distinct genotypes, referred to as somatic mosaicism by lineage 72 expansion in healthy tissues, have drawn attention to the factors underlying certain disorders [9, 10] . 73 Tissue-specific processes or particular microenvironmental changes leave unique imprints in genomes [9, 74 11] . With the advent of next-generation sequencing (NGS), characteristics of multiple mutagenic processes 75 have been revealed for the first time in tumors of various origins [7, [11] [12] [13] . For instance, smoking results 76 mainly in C>A transitions in lung cancers, while ultraviolet (UV) radiation leaves a footprint involving 77 CC>TT dinucleotide substitutions in skin cancers [7, 14] . A recent investigation showed distinct mutational 78 spectra in cultured adult stem cells (ASCs) of liver in comparison with those originating from the colon and 79 small intestine [9] . Moreover, mutation spectra are influenced by the genetic background of individuals. For 80 example, breast cancer patients having BRCA1 or BRCA2 germline mutations showed a specific mutational 81 signature in tumor genomes compared with patients carrying BRCA wild types [11] . The confounding of 82 different mutagenesis-related factors by the genetic background means that mutation accumulation patterns 83 differ among tissues and individuals. 84
Two mutational signatures (Signature 1 and Signature 5 in COSMIC) related to the deamination of 85 methylated cytosines have shown a feature of accumulation with age in a broad range of cell types. However, 86 5 the accumulation process does not seem to maintain a steady pace. Specifically, the mutation rate per cell 87 division varies during development, undergoing diverse biological changes prenatally, and in childhood and 88 adulthood [1] . De novo mutations in offspring increase with paternal age, and the accumulation rate in gonads 89 was estimated to be ~2 mutations per year [15] . More than twofold differences in variation have been 90 observed between families, possibly influenced by germline methylation [1] . Hence, factors that influence 91 the mutagenic processes may differ due to various developmental demands, such as the activities of stem 92 cells in tissue repair, exposure to environmental factors, and tissue-specific functions [7, 9] . In addition, the 93 changes in mutational profile in cultured cells also reflect the genetic drift that occurs during clonal 94 expansion of the cell population carrying multiple pre-existing mutations [16] . 95
The large majority of knowledge on somatic mutation has been obtained from genomic analyses of cancer 96 or noncancer diseases, animal models, and cultured cells. However, despite the importance of analyzing the 97 generation and subsequent effects of somatic mutations in normal tissues, studies on their mutation profiles 98 are limited due to not only difficulties in obtaining appropriate tissues from healthy individuals, but also the 99 scarcity of cells carrying mutations [17] [18] [19] . Although great effort has been made on analyzing somatic 100 mutation profile on various tissue including skin, liver, esophagus, and colon, our knowledge of the mutation 101 spectrum and its dynamic nature in healthy individuals remains inadequate [6, 10, 20, 21] . 102
To obtain the somatic mutation spectrum in healthy individuals, in this study we first conducted optimized 103 6 of increased sensitivity and accuracy due to multiple steps of optimization (S1 Fig, Methods , S1 Appendix). 114
First, we analyzed five specimens from the volunteer M0038 annually for 4 years, including 2 blood and 3 115 sperm samples (S1 Table) . In both tissues, one de novo mutation was identified and its variant allele fraction 116 (VAF) reached 0.4 +/-0.02 in all samples. Overall, 36 cross-tissue mutations, with VAF of 0.002 to 0.434, 117
were shared by at least one blood and one sperm sample ( Fig 1A, S2 Fig, and S2 Table) . They were likely to 118 occur before tissue differentiation, considering the previous speculation that some cells may contribute to 119 multiple tissues at the early stages of embryo development [22] . For tissue-specific mutations, four common 120 postzygotic mutations were detected in all of the whole-blood samples, and 16 common mutations were seen 121 in all three sperm samples ( Fig 1A-B ). Especially, VAFs for these mutations were all consistent across the 122 samples. 123 bottom). One de novo mutation occurred before fertilization (top). Thirty-six mutations were shared by at least one sperm 126 sample and one blood sample. In contrast with the 16 shared common mutations found in sperm samples but not in blood, and 127 only four blood specific mutations were shared by both ages in blood. (B) Shared mutated genes in different samples of M0038.
128
Among the 57 mutations revealed in at least two samples besides the de novo mutation (CEP95), only one mutation (NF2, 129 0.09) was identified to have an allele fraction greater than 0.05. The scaled color represents the allele fraction of mutations. 7 the power to detect the relationship between amounts of postzygotic mutations and age, the former of which 144 varied from 124 to 813 (S1 Table) . Besides, these mutations had low recurrence rates. On average, only 2.7 145 (range 0-7) mutations were shared by two individuals (S2 Fig) , and none was found in more than two 146 individuals (S3 Table) . Moreover, these mutations also demonstrated reported mutational strand asymmetries caused by replication 171 8 and transcription (Methods). For the C>T or G>A transition at GpCpN and NpCpG, the C>T transitions were 172 likely to occur in the left-replication regions of the genome during DNA replication, whereas more G>A 173 transitions occurred in the right-replication regions ( Fig 2B and S7 Fig) . The genomic regions that encoded 174 genes on the reference strand exhibited a high density of C>T transitions, and the regions that encoded genes 175 on the complementary strand exhibited a high density of G>A transitions ( Fig 2C and S8 Fig) . Additionally, 176 sperm and blood cells from M0038 exhibited no significant difference in the patterns of postzygotic 177 mutations in the 96 mutation contexts and the mutational strand asymmetries ( To explore the whether these mutation patterns were also represented in other normal tissues, we collected 185 deep exome sequencing datasets (>200×) for one muscle sample from individual M0038 and normal blood 186 cell samples paired to tumor samples in three types of tumors, including esophageal squamous cell carcinoma 187 (ESCC), acute myelocytic leukemia (AML), and chordoma ( Fig 3A) . In addition, targeted sequencing data 188 for normal skin and single cell sequencing data for neurons were also analyzed ( Fig 3A) . The most significant 189 mutation feature observed in normal blood cells in these tumor studies was the enrichment of C>T transitions 190 at GpCpN sites, especially the GpCpC trinucleotide, consistent with above profiles in healthy individuals. 191
This kind of enrichment was also observed in the solid tissues, especially in neuron and muscle. Besides, all 192 paired tumor samples did not have this feature detected in their mutation profiles. These strongly suggests 193 that C>T at GpCpN sites commonly occurs in normal cells. 194 
215
Next, we merged deep exome sequencing datasets of all 56 normal tissue samples ( Fig 3A, Methods) , and 216 resolved Three mutational signatures, A, B and C ( Fig 3B) . Signature A is known to be associated with the 217 spontaneous deamination of methylated cytosine to thymine at NpCpG [7, 11, 27] , and Signature B is known 218 to be clock-like that the number of mutations in cancers and normal cells correlates with the age of the 219 individual. In addition to these two known signatures, we revealed a Signature C characterized by C>T 220 transitions at GpCpN trinucleotides, especially GpCpC sites. In particular, Signature C was found to be the 221 major contributor to somatic mutations detected in more than 30 normal samples ( Fig 3C) . 222 223
Epigenetic regulation may influence the proportion of mutational signatures in normal tissues 224
To identify genetic factors contributing to these mutational processes, we further performed whole-exome 225 association analysis with age as a covariate and the frequency of Signature A, B and C as the quantitative 226 value respectively, in our 40 unrelated normal samples (Methods). In total, 21 SNPs located in 18 protein 227 coding genes were shown to correlate with the proportions of Signature B (p < 1×10 −10 , permutation test; 228 10 Fig 3D and Table 1 ). Among these, 2 genes contained SET domain (enrichment P=0.031), which is an 229 important sequence feature of putative methyl transferase involved in histone methylation. The 2 genes are 230 PRDM9 (PR Domain 9), a zinc finger protein catalyzes the trimethylation of histone H3 lysine 4 (H3K4me3)  231 and KMT2C, a histone methyltransferase involve in leukemogenesis and developmental disorder [28] [29] [30] . 232
This result indicates mutations in epigenetic regulators may influence the proportion of signature B in normal 233 tissue. Moreover, two SNPs in NOTCH2 are associated with the proportion of Signature B and C, 234 respectively ( Table 1) . NOTCH2 is a key member of notch signaling pathway, which is important in 235 metazoan development and tissue renewal. Its inter-cellular domain can act as a transcription factor regulates 236 cell proliferation through controlling the expression of cycling D1 [31, 32] . Additionally, there is no SNPs 237 were significant associated with Signature A. These results demonstrate genetic background may influence 238 the mutational profile of each individual. 239 region. Therefore, the late stage mutations mingled with early ones may be distinguished in sequencing data 252 by VAF. As expected, mutations in muscle biopsy samples had significantly higher VAFs than those in blood 253 and sperm samples ( Fig 1C, P < 2 .2Í10 -16 ). We then divided muscle mutations into high VAF group, which 254 was more likely generated during embryo development, and low VAF group with the cutoff of VAF = 0.025. 255
In high VAF group, a significantly high proportion of C>T at GpCpC sites, the Signature C, was observed 256 (0.185 vs 0.06, S9 Fig) , suggesting the association of this mutation type with the development. 257
Hypoxia contributed to the occurrence of Signature C 258
We extracted sequencing datasets from The Cancer Genome Atlas (TCGA, Methods), including 3,827 259 samples from 22 types of tumor (S10 Fig) [2, 11, 33 ]. For the somatic mutation profiles, only a small 260 proportion of TCGA tumor samples (4%, 153/3,827) exhibited high numbers of C>T transitions in the 261 GpCpC context, of which 58 were clear cell renal cell carcinoma (CCRCC, S4 Table) . Notably, they were 262 distinguished from the rest of the 273 CCRCC samples in cluster analysis ( Fig 4A) and their similarity to 263 various types of normal tissue indicated that the same mutational processes occurred in both CCRCC and 264 normal cells. 265 12 By comparing the expression profiles of high-(58 samples) and low-GpCpC groups (the remaining 237 266 samples) of CCRCC, we resolved 145 differentially expressed genes (p < 0.05, chi-squared test; Fig 4B,  267 Methods). The most significant change in the high-GpCpC group was the increased transcription of 268 PPP1R12A (protein phosphatase 1 regulatory subunit 12A), which activates hypoxia-inducible factor (HIF)-269 1α [34] (adjust-p = 8.82×10 −5 , Benjamini-Hochberg method, Fig 4C) . Moreover, the Hippo pathway was 270 significantly enriched (p = 3.21×10 −5 ), which is associated with the transcriptional response to hypoxia [35-271 37]. Additionally, a slightly higher mutation rate of VHL (0.5 vs 0.43), whose product is involved in the 272 ubiquitination and degradation of HIF proteins [38] , was also observed in the high-GpCpC group (S5 Table) . 273
Taken together, these results suggest that increased activity of the HIF signaling pathway may contribute to 274 the high proportion of C>T transitions at GpCpC in these CCRCC samples. 275 
281
To test the roles of the HIF signaling pathway, we treated the human embryonic stem cell (hESC) line WA07 282 (WiCell Research Institute) with ML228, a direct activator of the HIF signaling pathway, through stabilizing 283 and activating the nuclear translocation of HIF-1α [39] (Methods, Fig 5A) . In the first stage, WA07 cells 284 were divided into two groups with ~1,000 cells in each. One group was treated with ML228 (0.125 nmol/ml) 285 for 15 days, and the other was treated with mock as a control. For the second stage, 10 cells were randomly 286 picked up from each group and expanded to ~1,000 cells with or without ML228, before harvesting for 287 exome sequencing with barcoding in library construction (Methods). As expected, a significantly high 288 proportion of C>T transitions at GpCpN was observed in ML228-treated cells in comparison with the level 289 in the control (0.17 vs. 0.07, p = 0.0091, chi-squared test; Fig 5B-C) . According to their proportions, we 290 divided all detected mutants into high-(VAF>0.05, mainly originating in the first stage) and low-allele-291 fraction mutations (VAF£0.05, mainly generated from the expansion process in the second stage). For both 292 types of mutation, higher accumulation of C>T transitions at GpCpN was observed in treated cells than in 293 the control (0.12 vs. 0.06 in the high allele fraction and 0.20 vs. 0.08 in the low allele fraction; S11 Fig) . 294 13 These results demonstrate that activation of the HIF signaling pathway can lead to C>T transitions at GpCpN. 295 In this study, based on postzygotic mutation profiles in healthy individuals from five trio families, we 305 discovered a signature characterized by C>T transitions in GpCpN trinucleotides as a major mutation type 306 shared by blood and sperm cells. A solid evidence for this mutational pattern as a hallmark trait of normal 307 tissues came from our observations in public or collaborative datasets eligible for analysis that such a 308 signature was observed in all normal tissues but only very limited cancers. Furthermore, a portion of CCRCC 309 with higher expression of HIF related pathways were featured by this mutation type, which lead to our 310 speculation that the hypoxia status may trigger such mutations in healthy people. To prove this proposal, we 311 designed an in vitro experiment using human embryo stem cell and we indeed observed accumulation of 312
Fig. 5. Activation of the HIF pathway by ML228 led to a high proportion of C>T transitions in the GpCpN context in
C>T transitions in GpCpN trinucleotides upon hypoxia induction. 313
Patterns of low VAF mutations in cell populations may be confounded by sequencing errors, and most 314 sequencing artifacts are due to DNA damage during extraction and acoustic shearing [40, 41] . We used 315 several strategies to assure the mutation authenticity. First, we largely reduced DNA damage before 316 sequencing by introduction of repair mix (p < 0.05, S12 Fig, see Methods) . We also used an optimized variant 317 calling method to mask sequencing noise which allowed us to produce high-confidence calls of postzygotic 318 mutations with VAF around 0.005 (See postzygotic mutation detection in Methods). Another challenge to 319 identify postzygotic mutations is that under certain situations, it is difficult to distinguish inherited variants 320 from postzygotic mutations due to inaccurate allele fractions in NGS sequencing. The theoretical values for 321 allele fraction of inherited heterozygous variations should be 0.5, however measured values usually range 322 14 from 0.2 to 0.6 due to unequal sequencing coverage of both alleles [42] . Actually, in our trio families, 323 inherited mutations may have allele fractions even around 0.1 to 0.3 in the sequencing data from siblings 324 (S13 Fig). Therefore, in addition to the filtering algorithms [43], we applied trio-based sequencing to 325 preclude inherited mutations, and in this way common sequencing errors in multiple individuals can also be 326 removed at the mean time. Validation of called variants with multiple methods ensured the confidence of our 327 observation (S3 Table) . Most importantly, in human embryo stem cells, we successfully generated our newly 328 identified mutational signature by introduction of mutagenesis ( Fig 5) , which greatly supported the reliability 329 of our findings. 330
To trace the mutagenesis process responsible for the signature, tumor samples in TCGA database provide us 331 an interesting clue that this signature specific to normal tissues can be only found in a portion of CCRCC, 332 known to be associated with activation of the HIF pathway [44] . Moreover, in recurrent glioblastoma, 333 featured by extremely hypoxic conditions in tumor microenvironment [45], a recent study showed that C>T 334 at GpCpC and GpCpT were enriched in their mutation spectrums (S2 Appendix and S14 Fig) [46] . 335
Meanwhile, paired transcriptome analysis for the high-GpCpC group of CCRCC demonstrated that their HIF 336 pathway was more active than that in the low-GpCpC group (Fig 4) . The induction of GpCpC mutation by 337 HIF signaling pathway was further validated in oligoclonal culture of hESCs. By directly activation of HIF1-338 α in oligoclonal hESCs using ML228, a previous well established assay [39] , and a specially designed two-339 step cell culture experiments ( Fig 5) , we successfully observed the significant accumulation of C>T at 340 GpCpN in mutational profiles. 341
In particular, we observed the same signatures for mutations in the blood and sperm tissues, indicating their 342 common mutagenesis process. In fact, such C>T at GpCpC sites could also be seen in mutation profile of 343 normal blood samples from a newborn baby study [47] . Notably, our samples carried high proportion of 344 mutations in the range of 0.01~0.05. This range of mutation fractions infer their occurrence within 20 cell 345 divisions after fertilization. In view of HIF pathway being crucial in oxygen-sensing to mediate tissue 346 adaptation to hypoxia, and hypoxic condition as a critical feature during embryonic development [48], we 347 believe that the C>T transitions at GpCpN sites may occur during the embryonic development under the 348 hypoxia status [49, 50] . In addition to our experimental validation with human stem cells, GpCpN mutations 349 can also be observed in normal neurons, in which the accumulation of C>T at GpCpN mutations were 350 15 significantly higher than those caused by deamination of methylated cytosines in NpCpG sites ( Fig 3A, S2  351 Appendix, and S15 Fig, p=0 It is the two unique features in our sequencing strategy, the utilization of liquid samples sperm and blood, 355 and the bulk sequencing without further separation or cloning, that allowed us to be able to capture those of 356 relative common mutations in each tissue that occurred in the early stage of a cell lineage. In contrast, 357 previous studies on postzygotic mutations mainly focusing on cancer somatic mutations, organoid mutations, 358 or de novo mutations [1, 5, 52] , most of which are private genomic changes in certain cell lineages across 359 all the life span. In these mutation spectra, therefore, early events only account for a small proportion and 360 possibly overwhelmed by all other mutations. This also explains why we observed the same signatures for 361 mutations in the blood and sperm tissues, indicating their common mutagenesis process most likely during 362 embryonic development. 363
Finally, integrating previously reported de novo mutations (S16 Fig) , somatic mutations in CCRCC, and our 364 results, we illustrate a mutational signature and corresponding active mutational processes during embryonic 365 and post-parturition development, as well as in tumor development ( Fig 6) . Across the individuals' lifespan, 366
C>T transitions at NpCpG trinucleotides due to spontaneous deamination constantly occur after fertilization. 367
In embryo development, the hypoxic environment triggers the occurrence and accumulation of C>T at 368 GpCpN sites. After birth, T>C transition was generated in normal cells based on de novo mutations. In 369 CCRCC, all types of mutation process were present. All of the aforementioned mutational processes can be 370 observed in all tissue types. In future investigations, samples of multiple normal tissues from one individual 371 should help to validate the molecular mechanism of hypoxia condition in mutation accumulation during 372 embryonic development. 373 
Materials and Methods
382
More detailed information is provided in S1 Appendix. 383
Samples and whole exome sequencing 384 Individuals F0061, M0070, M0072, M0074, and their parents were enrolled at Wenzhou Medical University 385 and samples from M0038 and his parents were collected at Beijing Institute of Genomics, Chinese Academy 386 of Sciences (CAS). The five samples were 5-33 years of age and included four males and one female (S1 387   Table) . All the details of whole exome sequencing analysis are summarized in S1 Appendix. This study was 388 approved by the ethics committees of both Beijing Institute of Genomics, CAS (NO. 2016H006) and the Eye 389
Hospital of Wenzhou Medical University (NO. KYK [2015] 2), and it was conducted in accordance with the 390 principles of the Declaration of Helsinki principles. All the participants were healthy and provided written 391 informed consent. 392
Postzygotic mutation detection 393
Based on the error estimation model (detailed information is provided in S1 Appendix), postzygotic 394 mutations in normal cells were detected by following several steps. Sequencing reads were aligned to the 395 human reference genome build GRCh37 using the BWA algorithm [53] after the removal of adapter segments 396 and the exclusion of reads with low Q-scores (S1 Appendix). Uniquely mapped reads with less than 3 397 mismatched bases were then processed using the error estimation model for all target regions, and variants 398 with ! > " were selected out. Then, variants with more than 1% of reads supporting an alternative allele 399 in either of the parents were removed to filter the inherited variants. In addition, due to the potential for 400 misalignment, we only kept the variants included in the strict mask regions of the 1000 Genomes Project The percentages of the 96 possible mutated trinucleotides in each sample, which were identified according 405 to the six classes of base substitutions and 16 sequence contexts immediately 5' and 3' to the mutated base, 406 were firstly calculated. The contexts of all mutations were extracted from the human reference genome build 407
GRCh37. The mutational signatures in the selected samples were then estimated using the nonnegative 408 matrix factorization (NMF) learning strategy. An appropriate number of mutational signatures was identified 409 by calculating the reproducibility value and reconstruction error for all samples. Each mutational signature 410 was finally displayed with the proportions of the 96 trinucleotides, and its contribution to each sample was 411 estimated. 412
Cell culture and molecular barcoded whole exome sequencing 413 The WA07 (WiCell Research Institute) cells were divided into two groups with ~1,000 cells each and 414 maintained in the human pluripotent stem cell chemical-defined medium (hPSC-CDM TM , Baishou 415 Biotechnology Co. LTD) according to the protocol. One group was treated with ML228 at 0.125 nmol/ml 416 and the other group was treated with mock as the control. Both two groups were cultured for 15 day and 417 cells received fresh medium with/without ML228 every other day. Then ~10 cells were randomly selected 418 from each group and cultured in the aforementioned medium with/without ML228 (0.125 nmol/ml), 419 respectively. Cells received fresh medium with/without ML228 every five days. Molecular barcoded whole 420 exome sequencing was performed on each group of cells after expanded to ~1,000 cells. Genomic DNA of 421 cultured expanded WA07 cells were extracted with a QIAamp DNA Mini Kit (Qiagen), per the 422 manufacturer's protocols. Partition barcoded libraries were then prepared based on the Chromium Exome 423 Solution (10X Genomics) and the exome target regions was enriched by SureSelect Human All Exon V5 Kit 424 (Agilent) according to the protocols. The target-enriched libraries with molecular barcoding were 425 subsequently sequenced on a HiSeq 4000 (Illumina) with 150-bp paired-end reads. 426
Mutation detection in hESCs 427
The exome sequencing data with molecular barcodes of WA07 cells was analyzed with the Long Ranger 428 (10X Genomics). Then, the mutations which contained multiple molecular barcodes in the mismatched reads 429 were kept. And to reduce the false positive rate, we removed the mutations which contained both two allele 430 types in one molecular barcode in the site. 431
Availability of data and materials 432 18 All sequencing data generated during the current study are available in the Genome Sequence Archive 433 (http://gsa.big.ac.cn) with the accession number of CRA000071. Sources of the public tumor data used in 434 this study are provided in the S1 Appendix. 435
